Moderna Inc said it has received an additional $472 million from the US government's Biomedical Advanced Research and Development Authority (BARDA) to support development of its novel coronavirus vaccine, according to Reuters.

The US-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna's vaccine candidate.

BARDA's total funding for the experimental vaccine of Moderna, the first in the United States to begin human trials of a coronavirus vaccine, is now about $955 million.